![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Amgen, UCB’s Osteoporosis Candidate Shines in Phase 3 Trial
Amgen, UCB’s Osteoporosis Candidate Shines in Phase 3 Trial
Amgen and UCB’s romosozumab met its primary endpoints in a Phase 3 study by reducing new vertebral fractures in postmenopausal women with osteoporosis through months 12 and 24.
The candidate also met a secondary endpoint of reducing the incidence of clinical fractures through 12 months, but missed its secondary endpoint of reducing the incidence of non-vertebral fractures through months 12 and 24.
Upcoming Events
-
21Oct